Brief: Biophytis To Present Phase 2-3 Cova Study Results
09/03/2023 07:19
March 9 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS TO PRESENT POSITIVE RESULTS OF PHASE 2-3 COVA
STUDY AT
ERS 2023 21ST LUNG SCIENCE CONFERENCE
Source text for Eikon: ID:nEQ8Ktr6ta
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon